# Istituto di Candiolo IRCCS (FPO)

Source: https://onco.cc/institutions/candiolo/  
OnCo record `candiolo` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Piedmont's cancer institute near Turin, a world reference for colorectal cancer genomics, patient-derived xenografts and MET biology.

## Summary

The Candiolo Cancer Institute is a private not-for-profit IRCCS run by the Fondazione Piemontese per l'Oncologia with the University of Turin. Paolo Comoglio's laboratory discovered and characterised the MET oncogene, Livio Trusolino and Andrea Bertotti built a large colorectal cancer patient-derived xenograft platform ('xenopatients') that identified HER2 amplification as a target and led to the HERACLES trial of trastuzumab plus lapatinib, and Alberto Bardelli's group pioneered liquid biopsy tracking of resistance to anti-EGFR therapy. The hospital provides surgery, radiotherapy, medical oncology and a phase 1 unit, and hosts a large biobank and a molecular tumour board for the Piedmont network.

## Fields

- Kind: Institution
- Last checked: 2026-09-09
- Also known as: Candiolo Cancer Institute; Fondazione Piemontese per l'Oncologia; IRCCS Candiolo; INOC - Istituto Nazionale Oncologico Candiolo; Istituto Nazionale Oncologico Candiolo
- City: Candiolo, IT
- Type: cancer-center
- Website: https://www.fpoircc.it/en/

## Sources

- Homepage: https://www.fpoircc.it/en/
- Research: https://www.fpoircc.it/en/research/

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [Patient-derived xenografts](https://onco.cc/technologies/pdx-models/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [EGFR](https://onco.cc/targets/egfr/), [HER2](https://onco.cc/targets/her2/), [KRAS](https://onco.cc/targets/kras/), [MET](https://onco.cc/targets/met/)
- drugs: [Trastuzumab](https://onco.cc/drugs/trastuzumab/)
- terms: [Circulating tumour DNA (ctDNA)](https://onco.cc/terms/ctdna/), [Drug resistance (primary and acquired)](https://onco.cc/terms/resistance/)
- people: [Alberto Bardelli](https://onco.cc/people/alberto-bardelli/), [Andrea Agnelli](https://onco.cc/people/andrea-agnelli/), [Anna Sapino](https://onco.cc/people/anna-sapino/)
- bottlenecks: [Acquired resistance to every therapy](https://onco.cc/bottlenecks/b-resistance/), [Lab models that fail to predict what happens in patients](https://onco.cc/bottlenecks/b-preclinical-models/)
- key papers: [A molecularly annotated platform of patient-derived xenografts identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer](https://onco.cc/key-papers/paper-bertotti-xenopatients-her2-cetuximab-resistant-colorectal-cancer-discov-2011/), [Assessment of a HER2 scoring system for colorectal cancer: results from a validation study](https://onco.cc/key-papers/paper-valtorta-her2-scoring-colorectal-heracles-mod-pathol-2015/), [Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES)](https://onco.cc/key-papers/paper-sartore-bianchi-heracles-trastuzumab-lapatinib-lancet-oncol-2016/), [Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer](https://onco.cc/key-papers/paper-misale-kras-acquired-resistance-anti-egfr-colorectal-nature-2012/), [Stromal contribution to the colorectal cancer transcriptome](https://onco.cc/key-papers/paper-isella-stromal-contribution-colorectal-transcriptome-nat-genet-2015/)

---
JSON: https://onco.cc/api/v1/entities/candiolo.json